42 results about "Corticotropins" patented technology

The invention discloses an automatic sleep staging method of a single-lead electroencephalogram. A training model comprises a feature extraction module and a staging optimization module, the feature extraction module comprises CNNs (convolutional neural networks) (1) and an Softmax layer (2), the staging optimization module comprises bi-directional LSTM (long-short term memory) recurrent neural networks (3) and a CRF (corticotropin releasing factor) conditional random field model (4), and the CNNs (1), the Softmax layer (2), the LSTM recurrent neural networks (3) and the CRF conditional random field model (4) are sequentially connected. The method only needs the single-lead sleep electroencephalogram, portable and comfortable sleep monitoring requirements are met, temporal and spatial characteristics of the electroencephalogram are sufficiently excavated according to the convolutional neural networks and the recurrent neural networks, the method has dynamic learning capacity and can adapt to great changed environments of diseases, the staging optimization module sufficiently considers relation between the front and the back of N 30s of electroencephalogram data, and the staging accuracy and the generalization ability of the model are improved.

A compound represented by the formula:

[wherein R¹ is methoxy, methylthio, ethyl, etc.; R⁵ and R⁶ are each independently cyclopropylmethyl, (4-tetrahydropyranyl)methyl, etc.; and two of R⁴⁰, R⁴¹ and R⁴² are C_1-6 alkoxy while the remaining one is methoxymethyl, etc.], a salt thereof, or a hydrate of the foregoing. This compound has excellent antagonism against corticotropin-releasing factor receptor.

Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.

A compound represented by the formula:

[wherein R¹ is methoxy, methylthio, ethyl, etc.; R⁵ and R⁶ are each independently cyclopropylmethyl, (4-tetrahydropyranyl)methyl, etc.; and two of R⁴⁰, R⁴¹ and R⁴² are C_1-6 alkoxy while the remaining one is methoxymethyl, etc.], a salt thereof, or a hydrate of the foregoing. This compound has excellent antagonism against corticotropin-releasing factor receptor.

In some aspects, the invention relates to methods for increasing insulin-sensitivity and/or decreasing insulin secretion in an individual by reducing or inhibiting corticotropin releasing factor 2 (CRFR2) signaling. CRFR2 antagonists may block agonism by one or more CRFR2 agonist, for example Ucn 2 or Ucn 3. Methods according to the invention may be use to treat a variety of metabolic diseases such as type 2 diabetes, metabolic syndrome, nonalcoholic fatty liver disease, polycystic ovarian syndrome and obesity.

The present invention provides transgenic mice deficient in corticotropin releasing factor receptor 2 (CRFR2). Mice deficient for CRFR1 exhibit decreased anxiety-like behavior and a decreased stress response. In contrast, CRFR2 null mutant mice are hypersensitive to stress and display increased anxiety-like behavior. These mice are useful for the study of anxiety, depression, and the physiology of the HPA axis. CRFR2 null mutant mice also exhibit increased angiogenesis in all tissues examined. Thus, CRFR2 antagonists may be used to stimulate angiogenesis for the treatment of various conditions. In contrast, CRFR2 agonists may be used to inhibit angiogenesis. A combination of urocortin and bFGF was observed to stimulate rapid hair growth.

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

A method for treating or preventing a host mammal that exhibits aversive signs and symptoms present during protracted abstinence or extended discontinuation syndromes as seen after cessation of compulsive activity, behaviors, or substance use is disclosed. That method comprises administering to a host mammal in need a pharmaceutical composition containing an aversive sign and symptom lessening amount a compound of Formula I or a pharmaceutically acceptable salt thereof dissolved or dispersed in a physiologically acceptable diluent, and repeating the administration as needed,

wherein W, X, Y and Z, R¹ and Ar are defined within. Data are provided in rats as host mammals using behavioral models dependent on the CRF₁ system: defensive burying, alcohol dependence, cocaine dependence and nicotine dependence. A contemplated method also is useful for inhibiting relapse of such a behavior. A contemplated method also is useful for treating substance-related or substance-induced psychiatric disorders that include aversive signs and symptoms.

Screening methods for identifying compounds that bind to or activate corticotropin releasing factor₂ receptors (CRF₂R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF₂Rs or of CRF₂R signal transduction pathways, increase CRF₂R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF₂R agonists, antibodies to CRF₂R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF₂R as the target for intervention and methods for treatment of muscular dystrophies are described.

This invention provides for an improved method for differentially diagnosing ACTH-dependent Cushing's syndrome. Current practice for differentially diagnosing ectopic ACTH syndrome and Cushing's Disease measures relative ACTH concentrations from the inferior petrosal venous sinus compared to fluid obtained from a periphery venous sample. This is performed before and after administration of exogenous corticotropin releasing factor, or after administration of metyrapone. This invention uses glucocorticoid receptor antagonists to induce release of endogenous CRH which stimulates ACTH to increase in patients with ectopic ACTH syndrome but not in those with Cushing's Disease.

The invention relates to a health-care wine which is prepared from the following raw materials in parts by weight: 1g of broomrape, 1g of safflower, 1g of gromwell, 0.5g of cynomorium songaricum, 0.5g of hemlock parsley and 2000g of 20-70% (V/V). The health-care wine can improve the immunologic function, is capable of removing free radicals and resisting aging, has the saccharide corticotropin-like functions, and can resist platelets from aggregation. The rich inorganic ions can enhance the movements of the bowels and perform the function of loosening the bowel to relieve constipation. The health-care wine can be used for treating multiple diseases, and has the anti-inflammatory and antineoplastic effects.

Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.